Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZOE.L Regulatory News (ZOE)

  • There is currently no data for ZOE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Novel Food Application

6 Apr 2021 07:00

RNS Number : 4600U
Zoetic International PLC
06 April 2021
 

For immediate release

6 April 2021

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION 11 OF THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS 2019/310

 

Zoetic International plc

('Zoetic', the 'Company' or the 'Group')

 

Zoetic's Novel Food Application passes FSA administrative check

 

Zoetic, the international CBD group, is pleased to provide the following update on its efforts to gain regulatory approval by the UK Food Standards Agency ('FSA' or the 'Agency') for its products in the United Kingdom. This FSA approval is now required for CBD products to be sold in the UK. This applies to all CBD brands and not only those owned by Zoetic.

 

Overview

· The FSA announced on 13 February 2020 that businesses must submit a novel food authorisation application by 31 March 2021 if they wish to have their CBD products sold in the UK. CBD products without the authorisation and subsequent validation would not be allowed to be sold in the UK.

 

· Zoetic submitted an application in conjunction with the European Industrial Hemp Association's ('EIHA') Novel Food Consortium.

 

· Zoetic received notification from EIHA that its CBD products passed the regulator's administrative check and can remain on sale in the UK.

 

· Official validation will be granted pending the results of toxicological studies on CBD, expected in the coming months.

 

Following the submission of a legal dossier, made in partnership with the EIHA's Novel Food Consortium, the Group has now received confirmation that its natural isolate CBD products can continue to be sold in the UK as the application has passed the regulator's administrative check. Official validation is expected to follow in the coming months, pending the results of toxicological studies of the CBD contained in its products.

 

Trevor Taylor, Co-CEO of Zoetic, said: "The FSA's regulation marks a pivotal moment for the CBD industry and Zoetic welcomes the Agency's efforts to protect consumers from CBD products that do not meet the necessary standards. We submitted our application with EIHA, a highly respected European industry association, and are thrilled that the submission has passed the initial check and we are now one step closer to full validation. As always, we are committed to rigorous quality assurance processes at every step because our success as a company is indivisible from the quality of our products."

 

Further progress is expected in the coming months. More information can be found on the EIHA website.

 

- Ends -

 

About the European Industrial Hemp Association

The European Industrial Hemp Association ('EIHA') represents the collective interests of key stakeholders in the hemp industry across the European Union ('EU'). Their primary function is to advocate for the industry by contributing to international policy-making consultations and decisions by European regulators. EIHA also operates a Novel Food Consortium which aims to secure the necessary regulatory approvals for members to continue producing and selling their products.

 

Publication on website

 

A copy of this announcement is also available on the Group's website at www.zoeticinternational.com

 

Media enquiries:

Zoetic International plc

c/o Buchanan

Trevor Taylor, Co-CEO

Antonio Russo, Co-CEO

 

 

Allenby Capital Limited (Financial Adviser and Broker)

+44 (0) 20 3328 5656

Nick Harriss (Corporate Finance)

 

Nick Naylor (Corporate Finance)

 

Guy McDougall (Equity Sales)

 

 

 

Buchanan

 

Henry Harrison-Topham / Jamie Hooper / Ariadna Peretz

Tel: +44 (0) 20 7466 5000

zoetic@buchanan.uk.com

www.buchanan.uk.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDKPBDDBKBKQK
Date   Source Headline
25th Jun 20204:00 pmRNSHolding(s) in Company
24th Jun 20203:00 pmRNSHolding(s) in Company
22nd Jun 20207:00 amRNSHolding(s) in Company
15th Jun 20207:00 amRNSHolding(s) in Company
3rd Jun 20209:05 amRNSSecond Price Monitoring Extn
3rd Jun 20209:00 amRNSPrice Monitoring Extension
2nd Jun 20207:00 amRNSSubscription for Equity
1st Jun 20207:00 amRNSNew Distribution Agreement and Trading Update
29th May 20207:00 amRNSFiling of Patents
27th May 20207:00 amRNSSale of DTU Interest and Kansas Nitrogen Assets
15th May 20207:00 amRNSTrading Update
11th May 20203:36 pmRNSHolding(s) in Company
6th May 20202:34 pmRNSHolding(s) in Company
29th Apr 20207:00 amRNSBoard and Strategy Changes, and Trading Update
3rd Apr 20207:00 amRNSIssue of Equity
1st Apr 20207:00 amRNSCOVID-19 Update
26th Mar 202011:05 amRNSSecond Price Monitoring Extn
26th Mar 202011:00 amRNSPrice Monitoring Extension
26th Mar 20207:00 amRNSIssue of Equity
20th Mar 20207:00 amRNSCOVID-19 Update
5th Mar 20207:00 amRNSOperational update
12th Feb 20207:00 amRNSSubscription to raise £0.39 million
5th Feb 20207:00 amRNSTrading Update
23rd Dec 20197:00 amRNSInterim Results
16th Dec 20197:00 amRNSSettlement of Diversion Debt & Notice of Results
28th Nov 20197:00 amRNSResult of General Meeting
25th Nov 20197:00 amRNSTrading Update
14th Nov 20199:19 amRNSIssue of Equity
13th Nov 20192:06 pmRNSSecond Price Monitoring Extn
13th Nov 20192:00 pmRNSPrice Monitoring Extension
11th Nov 20197:00 amRNSListing on the OTC
8th Nov 20199:01 amRNSIssue of Equity
7th Nov 20197:00 amRNSNotice of General Meeting
1st Nov 20192:05 pmRNSSecond Price Monitoring Extn
1st Nov 20192:00 pmRNSPrice Monitoring Extension
29th Oct 20194:42 pmRNSSecond Price Monitoring Extn
29th Oct 20194:35 pmRNSPrice Monitoring Extension
21st Oct 20197:00 amRNSIssue of Shares
18th Oct 201911:05 amRNSSecond Price Monitoring Extn
18th Oct 201911:00 amRNSPrice Monitoring Extension
8th Oct 20197:00 amRNSAdoption of new share option scheme
4th Oct 20197:00 amRNSTrading Update
17th Sep 20197:00 amRNSDirectorate Change
12th Sep 201912:30 pmRNSDirector/PDMR Shareholding
9th Sep 201911:15 amRNSChange of Name
6th Sep 201910:30 amRNSDirector/PDMR Shareholding
4th Sep 201911:05 amRNSSecond Price Monitoring Extn
4th Sep 201911:00 amRNSPrice Monitoring Extension
4th Sep 20197:00 amRNSDirectorate Change
30th Aug 20194:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.